21 stories mentioning CYTKUpdated 1d ago
Every FINWIRES story that references CYTK, newest first.
Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 30, 2026, sold 14,000 shares in Cytokinetics (CYTK) for $1,118,320. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000086/xslF345X05/form4.xml
Cytokinetics (CYTK) said Thursday that the United Kingdom's Medicines and Healthcare products Regulatory Agency has granted aficamten marketing authorisation across the UK for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.Guidance from the National Institute for Health and Care Excellence states that aficamten can be used to treat symptomatic obstructive hypertrophic cardiomyopathy in eligible adults with NYHA class II to III, in England and Wales, the company said.Aficamten can only be used as an add-on to individually optimised standard care including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or alone if these treatments are contraindicated, Cytokinetics said.The company said that the MHRA's assessment was based on data from its phase 3 SEQUOIA-HCM study in 282 adults.Shares of the company were up 2.2% in Thursday trading.Price: $80.30, Change: $+1.91, Percent Change: +2.44%
Robert I Blum, Director, President & CEO, on July 27, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $606,525. Following the Form 4 filing with the SEC, Blum has control over a total of 381,986 common shares of the company, with 377,820 shares held directly and 4,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000085/xslF345X05/form4.xml
Fady Ibraham Malik, Executive Vice President, Research & Development, on July 21, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $282,065. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000084/xslF345X05/form4.xml
Robert I Blum, Director, President & CEO, on July 13, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $615,150. Following the Form 4 filing with the SEC, Blum has control over a total of 381,986 common shares of the company, with 377,820 shares held directly and 4,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000077/xslF345X05/form4.xmlPrice: $81.68, Change: $-0.56, Percent Change: -0.68%
Andrew Callos, Executive Vice President, Chief Commercial Officer, on July 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,287,000. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000073/xslF345X05/form4.xml
Sung Lee, Executive Vice President, Chief Financial Officer, on June 29, 2026, sold 3,134 shares in Cytokinetics (CYTK) for $266,390. Following the Form 4 filing with the SEC, Lee has control over a total of 63,221 common shares of the company, with 63,221 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000070/xslF345X05/form4.xml
Cytokinetics (CYTK) is set up for stronger sales and potential stock gains as its new heart drug Myqorzo continues to build momentum, UBS Securities said Monday in a report.Myqorzo treats obstructive hypertrophic cardiomyopathy, a condition where the heart muscle becomes too thick and restricts blood flow. Symptoms often include shortness of breath, chest pain, dizziness and fatigue. UBS said doctors in its survey were enthusiastic about using Myqorzo because of its safety profile and easier monitoring requirements compared with existing treatments.The drug also recently succeeded in a late-stage study for non-obstructive HCM, a related form of the disease, and UBS said that could open a second wave of demand if approved, potentially starting in late 2027.UBS expects Myqorzo to become a key product for Cytokinetics and forecasts peak annual sales of about $4 billion for obstructive HCM alone, with additional upside from non-obstructive HCM. Earnings updates may help support the stock as the launch progresses, the report said.UBS raised its rating on Cytokinetics stock to buy from neutral and increased its price target to $115 from $69.Price: $85.46, Change: $+3.27, Percent Change: +3.97%
Cytokinetics (CYTK) has an average rating of buy and mean price target of $107.53, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Andrew Callos, Executive Vice President, Chief Commercial Officer, on June 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,111,200. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000065/xslF345X05/form4.xml
Robert I Blum, Director, President & CEO, on May 27, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $579,075. Following the Form 4 filing with the SEC, Blum has control over a total of 396,996 common shares of the company, with 392,830 shares held directly and 4,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000063/xslF345X05/form4.xml
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 19, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $264,915. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000053/xslF345X05/form4.xml
Health care stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.1%.Cytokinetics (CYTK) shares fell more than 1% premarket after the company said late Wednesday it priced its upsized public offering of about 9.9 million shares at $71 a piece for gross proceeds of around $700 million.Catalyst Pharmaceuticals (CPRX) stock was gaining over 2% before the opening bell after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse, or amifampridine.Lifestance Health Group (LFST) shares rose 11% after the company reported higher Q1 earnings and revenue.
Cytokinetics' (CYTK) rapid growth of the Myqorzo drug and peak US opportunity in obstructive hypertrophic cardiomyopathy are yet to be fully priced in by investors, RBC Capital Markets said in a Tuesday research report.As Cytokinetics transitions from the clinical to the commercial stage, the brokerage said it expects upside on launch execution and potential merger optionality. If it continues to add 400 to 500 new patient starts monthly, it could result in substantial commercial growth through the year, the firm said.The absence of considerable inventory contribution supports the view that there is organic demand for Myqorzo as most of the operational hurdles have been worked through, according to the note.ACACIA-HCM to treat symptomatic non-obstructive hypertrophic cardiomyopathy is a "clear win" that can enable registration in this indication, according to the firm. RBC raised its probability of success forecast for the drug to 90% and 2035 US sales estimate to $1.30 billion, the firm said.The firm removed its speculative risk rating on the stock and boosted its price target to $119 per share from $101.Price: $73.59, Change: $-3.50, Percent Change: -4.54%
Cytokinetics (CYTK) has an average rating of buy and mean price target of $100.37, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Fady Ibraham Malik, Executive Vice President, Research & Development, on May 05, 2026, sold 3,500 shares in Cytokinetics (CYTK) for $270,795. Following the Form 4 filing with the SEC, Malik has control over a total of 153,902 common shares of the company, with 153,902 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000051/xslF345X05/form4.xml
Andrew Callos, Executive Vice President, Chief Commercial Officer, on May 01, 2026, sold 15,857 shares in Cytokinetics (CYTK) for $1,030,705. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000046/xslF345X05/form4.xml
Robert I Blum, Director, President & CEO, on April 29, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $447,150. Following the Form 4 filing with the SEC, Blum has control over a total of 411,996 common shares of the company, with 407,830 shares held directly and 4,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000044/xslF345X05/form4.xml
Edgewise Therapeutics (EWTX) faces near-term upside opportunity with Cytokinetics' (CYTK) upcoming readout from its Acacia trial, RBC Capital Markets said in a note Friday.The brokerage said that regardless of Cytokinetics' trial data, there may be positive readthroughs for Edgewise's EDG-7500 candidate, driving about 10% upside.A positive result from the Acacia readout would validate drugs for non-obstructive hypertrophic cardiomyopathy and suggest that development of iterative drugs like EDG-7500 can progressively drive better benefits, while an Acacia miss could mean a potentially uncontested market, according to the note.Follow-up data from Edgewise's Cirrus trial also has the potential to drive an about 10% upside, creating a "nice" catalyst path in Q2, while the company's Grand Canyon trial results could be the stock's largest catalyst this year, the brokerage said.RBC has an outperform, speculative risk rating on the stock, with a $50 price target.Price: $31.51, Change: $+0.28, Percent Change: +0.90%
Robert I Blum, Director, President & CEO, on April 15, 2026, sold 7,500 shares in Cytokinetics (CYTK) for $490,350. Following the Form 4 filing with the SEC, Blum has control over a total of 419,496 common shares of the company, with 415,330 shares held directly and 4,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000035/xslF345X05/form4.xml
Showing 1-20 of 21
